What it's for (Indications)
- Lamivudine, a synthetic nucleoside analog and a highly potent nucleoside reverse transcriptase inhibitor (NRTI), is primarily indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients.
- It is consistently prescribed as part of a multi-drug regimen, never as monotherapy for HIV-1, to achieve maximal viral suppression, prevent the emergence of resistance, and improve long-term clinical outcomes as per current antiretroviral therapy (ART) guidelines.
- Furthermore, lamivudine is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients aged 2 years and older who have evidence of active viral replication, persistent elevations in serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels, or histologically active disease.
- Its efficacy in managing both HIV-1 and HBV makes it a critical therapeutic option, particularly for patients co-infected with both viruses, necessitating careful consideration of dosing and potential interactions with other medications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The precise dosage of lamivudine varies based on the indication, patient age, and renal function. For the treatment of HIV-1 infection in adults, the recommended oral dosage is 300 mg once daily or 150 mg twice daily, always administered in combination with other antiretroviral agents. Pediatric dosing for HIV-1 is weight-based, typically 4 mg/kg twice daily or 8 mg/kg once daily, not exceeding 300 mg daily, and must be part of a combination regimen. For chronic hepatitis B virus (HBV) infection in adults, the recommended oral dosage is 100 mg once daily. Pediatric dosing for HBV is also weight-based, typically 3 mg/kg once daily, not exceeding 100 mg daily. Crucially, dosage adjustments are imperative for patients with renal impairment, as lamivudine is predominantly eliminated via the kidneys. Prescribers must consult official prescribing information for specific dose modifications based on the patient's estimated creatinine clearance (CrCl) to avoid drug accumulation and potential toxicity, thereby optimizing efficacy and safety. |
Safety & Warnings
Common Side Effects
- Patients receiving lamivudine may experience a spectrum of side effects, ranging from common and generally mild to less frequent but potentially severe.
- Common adverse events frequently reported include headache, nausea, diarrhea, abdominal pain, fatigue, malaise, insomnia, nasal symptoms, and cough.
- These reactions are typically transient and may resolve with continued therapy.
- More serious, albeit less common, adverse effects include pancreatitis, particularly noted in pediatric patients with advanced HIV disease or those concurrently receiving didanosine.
- Hematologic abnormalities such as neutropenia and anemia have been reported, necessitating periodic monitoring of complete blood counts.
- Peripheral neuropathy has also been observed in some individuals.
- Furthermore, a significant concern is the risk of severe acute exacerbations of hepatitis B in patients co-infected with HIV and HBV who discontinue lamivudine, requiring vigilant post-treatment monitoring of liver function for several months.
- Additionally, fat redistribution (lipodystrophy) and lactic acidosis (detailed in the Black Box Warning) are critical adverse events associated with NRTI class drugs.
Serious Warnings
- Black Box Warning: **Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including lamivudine.** This severe metabolic complication, characterized by elevated lactate levels, metabolic acidosis, and fatty liver, requires immediate discontinuation of the drug and intensive supportive care if suspected. Patients with risk factors such as obesity or prolonged nucleoside analog exposure may be at increased risk. **Severe acute exacerbations of hepatitis B have been reported in patients co-infected with HIV-1 and HBV who have discontinued lamivudine.** These exacerbations can be severe and potentially fatal. Therefore, hepatic function must be monitored closely with both clinical and laboratory follow-up for at least several months in patients discontinuing lamivudine. **Patients co-infected with HIV-1 and HBV should receive appropriate combination antiretroviral therapy to treat HIV-1; lamivudine monotherapy is not appropriate for the treatment of HIV-1 infection, as it can lead to the rapid development of lamivudine-resistant HIV-1 strains.** Adherence to these warnings is crucial for patient safety.
- Several critical warnings are associated with lamivudine therapy, demanding careful patient assessment and monitoring.
- A paramount concern is the potential for severe acute exacerbations of hepatitis B in patients co-infected with HIV-1 and HBV who discontinue lamivudine.
- This risk necessitates close clinical and laboratory monitoring of hepatic function for at least several months after treatment cessation.
- For patients with unrecognized HIV-1 infection being treated for HBV monotherapy, there is a substantial risk of developing lamivudine-resistant HIV-1 strains; thus, comprehensive HIV-1 testing is mandatory prior to initiating lamivudine for HBV, and co-infected patients must receive full combination antiretroviral therapy for HIV.
- Immune Reconstitution Inflammatory Syndrome (IRIS) has been reported in HIV-infected patients initiating combination antiretroviral therapy, including lamivudine, manifesting as an inflammatory response to pre-existing opportunistic infections or indolent pathogens.
- Clinicians should also be aware of potential changes in body fat distribution (lipodystrophy) and reductions in bone mineral density associated with long-term antiretroviral therapy, requiring ongoing assessment and management.
How it Works (Mechanism of Action)
Lamivudine (3TC) functions as a synthetic nucleoside analog of cytidine, specifically classified as a nucleoside reverse transcriptase inhibitor (NRTI). Upon oral administration, lamivudine is rapidly absorbed and undergoes intracellular phosphorylation by host cell kinases to its active metabolite, lamivudine triphosphate. This active triphosphate form then acts as a potent competitive inhibitor of both the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the hepatitis B virus (HBV) reverse transcriptase. By mimicking the natural substrate, deoxycytidine triphosphate (dCTP), lamivudine triphosphate is preferentially incorporated into the nascent viral DNA chain. Critically, once incorporated, lamivudine triphosphate lacks a 3'-hydroxyl group, which is essential for further phosphodiester bond formation, leading to premature chain termination of viral DNA synthesis. This mechanism effectively halts the replication cycles of both HIV-1 and HBV, thereby reducing viral load and mitigating disease progression, underscoring its dual antiviral utility.